United Therapeutics Corporation (UTHR) Stock Overview
Explore United Therapeutics Corporation’s financial performance, market position, analyst ratings, and future outlook.
United Therapeutics Corporation (UTHR)
Key Financials
Key Financials
Market Cap
20.6B
P/E Ratio
16.02
EPS (TTM)
$27.95
ROE
0.20%
UTHR Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of United Therapeutics Corporation (NASDAQ: UTHR) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, United Therapeutics Corporation's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of UTHR on the NASDAQ shows an RSI of 41.45, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $515.56 for the NASDAQ listing.
Key metrics behind United Therapeutics Corporation's NASDAQ-traded stock include a P/E ratio of 16.02 and a market capitalization of 20.6B. Combined with our AI analysis, these give both institutional and retail investors a clear view of UTHR on the NASDAQ.